Volume : 13, Issue : 04, April – 2026
Title:
CAUSE ANALYSIS OF RISK FACTORS, DRUG RESSISTENCE AND CO MORBIDITIES OF TUBERCULOSIS (TB) PATIENTS
Authors :
Dr. Atharva Gajanan Chapke*, Dr. Mrunali Sudhir Jane
Abstract :
Tuberculosis (TB) remains a major global public health concern, significantly influenced by multiple risk factors, drug resistance, and associated co-morbidities. The present study titled “Cause Analysis of Risk Factors, Drug Resistance and Co-morbidities of Tuberculosis (TB) Patients” was conducted to evaluate the epidemiological, clinical, and behavioral determinants affecting TB patients. A cross-sectional observational study was carried out at G. G. Rathi Tuberculosis Hospital over a period of eight months (October 2023 to May 2024), including 119 patients diagnosed with pulmonary TB, extra-pulmonary TB, and multidrug-resistant TB.
Data were collected from patient case records and direct interviews using a structured data collection form and the Morisky Medication Adherence Questionnaire (MMAS-8). Descriptive statistical analysis was performed using SPSS. The results showed a higher prevalence of TB among males (68%) and rural populations (60%). Most patients were married (93%) and belonged to the middle socio-economic class (75%). Occupational analysis revealed that daily wage workers (50%) were more affected. Substance abuse was reported in 61% of patients, with alcohol being the most common (46%). Clinically, 90% of patients had drug-sensitive TB, while 10% had MDR-TB. Pulmonary TB was the most prevalent form (95%). Drug resistance was observed in 23% of patients, with rifampicin resistance and MDR each accounting for 37% of resistant cases. The majority of patients were in the disease control phase (64%) and received first-line therapy (75%). Co-morbidities were present in 46% of patients, with diabetes mellitus (26%) being the most common. Medication adherence assessment revealed that 62% of patients had high adherence, while 15% exhibited poor adherence.
In conclusion, the study highlights that tuberculosis is influenced by a combination of socio-demographic, behavioral, and clinical factors. Early diagnosis, improved patient education, adherence to therapy, and targeted interventions for high-risk populations are essential for effective TB control and prevention of drug resistance.
KEYWORDS: Tuberculosis; Risk factors; Drug resistance; Multidrug-resistant TB (MDR-TB); Co-morbidities; Medication adherence; MMAS; Socio-economic factors; Substance abuse; Pulmonary tuberculosis.
Cite This Article:
Please cite this article in press Atharva Gajanan Chapke et al., Cause Analysis Of Risk Factors, Drug Ressistence And Co Morbidities Of Tuberculosis (Tb) Patients, Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York: McGraw-Hill; 2008. p. 2085–348.
2. World Health Organization. Tuberculosis fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
3. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier; 2005.
4. Government of India. India TB Report 2018. Revised National Tuberculosis Control Programme (RNTCP); 2018.
5. Mohan H. Textbook of Pathology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers; 2010. p. 61.
6. Nachiappan AC, Rahbar K, Shi X, Barbosa EJ Jr, Shroff GS, Ocazionez D, et al. Pulmonary tuberculosis: role of radiology in diagnosis and management. Radiographics. 2017;37(1):52–72.
7. Ramirez-Lapausa M, Menendez-Saldana A, Noguerado-Asensio A. Extrapulmonary tuberculosis: an overview. Rev Esp Sanid Penit. 2015;17(1):3–11.
8. Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316–353.
9. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72(9):1761–1768.
10. Kumar SV, Deka MK, Bagga M, Kala MS, Gauthaman K. A systematic review of different types of tuberculosis. Eur Rev Med Pharmacol Sci. 2010;14(10):831–843.
11. World Health Organization. Drug-resistant tuberculosis: types and overview. Available from: https://www.who.int/tb/areas-of-work/drug-resistance-tb/types/en/
12. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, et al. Adverse drug reactions associated with first-line anti-tuberculosis regimens. Int J Tuberc Lung Dis. 2007;11(8):868–875.
13. Gohel H, Patel G, Shah E, Shah H, Dholakia H, Patel H. A cross-sectional study to assess non-adherence to anti-tuberculosis treatment and determinant factors among pulmonary TB patients.
14. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
15. Xu M, Markström U, Lyu J, Xu L. Detection of low adherence in rural tuberculosis patients using Morisky scale. Int J Environ Res Public Health. 2017;14(3):248.
16. Gube AA, Debalkie M, Seid K, Bisete K, Mengesha A, Zeynu A, et al. Assessment of anti-TB drug non-adherence and associated factors. Tuberc Res Treat. 2018;2018:1–7.
17. Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment: qualitative and quantitative study. BMC Health Serv Res. 2009;9:169.
18. Gholami K, Kamali E, Hajiabdolbaghi M, Shalviri G. Evaluation of anti-TB drug adverse reactions. Pharm Pract. 2006;4(3):134–137.
19. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects of anti-TB drugs. Am J Respir Crit Care Med. 2003;167(11):1472–1477.
20. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti-TB drugs. Pharmacoepidemiol Drug Saf. 2007;16(10):1104–1110.
21. Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse reactions in TB patients under DOTS therapy. PLoS One. 2013;8(6):e65037.
22. M’Imunya JM, Kredo T, Volmink J. Patient education for improving TB adherence. Cochrane Database Syst Rev. 2012;(5):CD006591.
23. Shahanas A. Effectiveness of TB Medication Therapy Adherence Clinic (TB-MTAC). [Doctoral dissertation]. Coimbatore: KMCH College of Pharmacy.
24. Sariem CN, Nanlir ZS, Banwat SB, Dapar MP. Factors influencing tuberculosis medication adherence in resource-limited settings.
25. Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. Impact of counselling on TB treatment adherence. Int J Tuberc Lung Dis. 1999;3(12):1073–1080.
26. World Health Organization. Global Tuberculosis Report 2022.
27. Ragan EJ. Impact of alcohol use on TB treatment outcomes: a systematic review. Int J Tuberc Lung Dis. 2020.
28. Caceres G, Calderon R, Ugarte-Gil C. Tuberculosis and comorbidities: challenges in diabetes and depression. J Clin Tuberc Other Mycobact Dis. 2022.
29. Perriot J, Underner M, Peiffer G. Tuberculosis and tobacco smoking. J Tuberc. 2018.
30. Carwile ME, Hochberg NS, Sinha P. Undernutrition and tuberculosis pandemic. J Clin Tuberc Other Mycobact Dis. 2022;27:100311.
31. Bates M, Marais BJ, Zumla A. Tuberculosis comorbidity with communicable and noncommunicable diseases. Cold Spring Harb Perspect Med. 2015.
32. Shaban D. Understanding tuberculosis basics. WebMD; 2023. Available from: https://www.webmd.com/lung/understanding-tuberculosis-basics